Biocon: anticancer biologics still largely unaffordable
This article was originally published in Scrip
India's largest biotechnology firm, Biocon, has highlighted how, despite differential pricing, medicines for certain non-communicable diseases such as cancer are still beyond the reach of many patients in developing nations.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…